Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed COO
|
|
Invivyd, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/27/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"INVIVYD ANNOUNCES APPOINTMENT OF SARA COTTER TO BOARD OF DIRECTORS WALTHAM, Mass., JULY 27, 2023 — Invivyd, Inc. , a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the appointment of Sara Cotter to its board of directors. Ms. Cotter brings extensive leadership experience spanning healthcare investment management and drug development. “Ms. Cotter's comprehensive knowledge of the biopharmaceutical industry, pairing both operating and capital markets expertise, make her an excellent addition to our board of directors,” said Dave Hering, Chief Executive Officer of Invivyd. “Her keen industry insights and impressive accomplishments in drug development and healthcare investing will be invaluable to Invivyd a..." |
|
| 06/29/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/25/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/02/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/23/2023 |
8-K
| Quarterly results |
| 03/06/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/09/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 12/06/2022 |
8-K
| Appointed COO|
Docs:
|
"FORM 8-K",
"Employment Agreement, by and between Invivyd, Inc. and Jeremy Gowler",
"INVIVYD APPOINTS JEREMY GOWLER AS CHIEF OPERATING AND COMMERCIAL OFFICER, PROMOTES PETE SCHMIDT, M.D., TO CHIEF MEDICAL OFFICER WALTHAM, MASS; December 06, 2022 - Invivyd, Inc. , a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Jeremy Gowler as chief operating and commercial officer, effective December 16, 2022, and the promotion of Pete Schmidt, M.D. to chief medical officer, effective immediately. In his new role Mr. Gowler will oversee operations and commercial activities for the company. Dr. Schmidt will be responsible for overseeing all medical, clinical development and regulatory activities at Invivyd. Dr. Ellie Hershberger, Invivyd's chief development officer, is departing from the..." |
|
| 11/17/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E... |
| 10/24/2022 |
8-K
| Quarterly results |
| 10/13/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"SEPARATION AGREEMENT October 12, 2022 Jane Henderson [***] [***] Re: Separation Agreement",
"Consulting Services Agreement, effective as of October 13, 2022, by and between Invivyd, Inc. and Fred Driscoll",
"Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform WALTHAM, MASS; October 13, 2022 - Invivyd, a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Fred Driscoll as interim CFO as well as headcount changes to align resources to its key programs. The changes are designed to improve capital efficiency by reallocating resources to programs and functions to support our key activities on an accelerated timeline. As part of the resource realignment, the company is building out additional discovery and early development positions and has eliminated several corporate and commercial positions, among others, to ..." |
|
| 09/13/2022 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 09/12/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/15/2022 |
8-K
| Quarterly results |
| 07/05/2022 |
8-K
| Quarterly results |
| 06/30/2022 |
8-K
| Quarterly results |
| 06/22/2022 |
8-K
| Quarterly results |
| 06/21/2022 |
8-K
| Quarterly results |
| 05/19/2022 |
8-K
| Quarterly results |
| 05/13/2022 |
8-K
| Quarterly results |
| 03/30/2022 |
8-K
| Quarterly results |
| 03/21/2022 |
8-K
| Quarterly results |
| 03/21/2022 |
8-K/A
| Quarterly results |
| 03/01/2022 |
8-K
| Quarterly results |
| 02/23/2022 |
8-K
| Quarterly results |
| 02/22/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Adagio Therapeutics Announces CEO Succession Plan Waltham, MA - February 18, 2022 - Adagio Therapeutics, Inc., , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced a Chief Executive Officer succession plan. Current Adagio CEO Tillman Gerngross, Ph.D. has communicated to the Chairperson of the Board of Directors of Adagio that he agreed in principle to resign from his position as CEO. Upon Dr. Gerngross's departure from the Company, the Board intends to appoint Mr. David Hering, M.B.A., who has served as the Company's Chief Operating Officer, as Interim Chief Executive Officer of the Company. Dr. Gerngross also agreed to transfer the duties of the ...",
"Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates" |
|
| 02/18/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/13/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 12/14/2021 |
8-K
| Quarterly results |
| 11/29/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 11/22/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Adagio Therapeutics Announces Expansion of Management Team and Board of Directors to Support Rapid Advancement and Commercial Readiness of ADG20 for COVID-19 Waltham, MA - Nov. 22, 2021 - Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that Jill Andersen has been appointed as chief legal officer, bringing over 20 years of legal, compliance and leadership experience in the pharmaceutical industry, government and private practice. In addition, Redonda Miller, M.D., MBA, president of The Johns Hopkins Hospital, and Ellen Marram, an experienced corporate director and board leader, and the former CEO of several consumer pr..." |
|
| 11/16/2021 |
8-K
| Regulation FD Disclosure Interactive Data |
|
|
|